Key result
Atenolol initiation after myocardial infarction without heart failure was associated with a lower risk of major adverse cardiovascular events compared with bisoprolol.
Why the study?
The effect of different beta-blockers on outcomes of patients without heart failure after myocardial infarction is not well-studied.
Does atenolol reduce major adverse cardiovascular events compared to bisoprolol in patients with a new myocardial infarction without heart failure?
Cohort (n=11,558)
Yes
Does atenolol reduce major adverse cardiovascular events compared to bisoprolol in patients with a new myocardial infarction without heart failure?
In patients with a new myocardial infarction without heart failure, initiation of atenolol was associated with a significantly lower risk of major adverse cardiovascular events at 2 years compared to bisoprolol.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We believe that the evidence still supports beta blockers for patients with a large myocardial infarction that experience heart failure, but for patients with no signs of heart failure and a normal ejection fraction, this trial establishes that there's no indication that routine use of beta blockers is beneficial.”
May favor atenolol over bisoprolol for MACE reduction post-MI without HF; hypothesis-generating and requires RCT confirmation.
BACKGROUND: Beta-blockers are a cornerstone of therapy following myocardial infarction. The effect of different β-blockers on the outcomes of patients without heart failure after myocardial infarction is not well-studied. METHODS: This observational cohort study used administrative data from French National Health Data System. Eligible patients were 18 years of age or older, hospitalized in the Paris area between January 1, 2008, and December 31, 2018, with a new myocardial infarction, and were dispensed either atenolol or bisoprolol within 2 days of hospital discharge. Patients prescribed β-blockers or loop diuretics or with a recorded diagnosis of heart failure (based on International Classification of Diseases, 10th Revision codes) during the 2 years preceding hospital discharge were excluded. Outcomes were followed for up to 2 years following hospital discharge and included major adverse cardiovascular events (cardiac arrest, all-cause mortality, reinfarction, stroke, or hospitalization for heart failure) (primary outcome) and all-cause mortality (secondary outcome). Targeted maximum likelihood estimation was used to estimate the average treatment effects (ATEs) comparing patients initiated on atenolol versus bisoprolol. RESULTS: Among 11,558 patients, 1523 (13.2%) initiated atenolol and 10,035 (86.8%) initiated bisoprolol within 2 days of discharge. Comparing the atenolol group to the bisoprolol group, the ATE was 2.9 percentage points (95% confidence interval [CI], 1.1-4.7) for major adverse cardiovascular events and 0.6 percentage points (95% CI, -0.2 to 1.3) for all-cause mortality. The weighted proportions of patients experiencing major adverse cardiovascular events were 10.8% and 14.1% in the atenolol and bisoprolol groups, respectively. The weighted proportions of patients experiencing all-cause mortality were 1.4% and 2.2% in the atenolol and bisoprolol groups, respectively. CONCLUSIONS: Among patients without recorded characteristics in an administrative database suggesting the presence of heart failure, initiation of atenolol after myocardial infarction was associated with a lower risk of major adverse cardiovascular events, but not all-cause mortality, at 2 years compared with bisoprolol. (Funded by PRAIRIE and others.).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Laurenceau et al. (2026) conducted a cohort in Myocardial Infarction without Recorded Heart Failure (n=11,558). Atenolol vs. Bisoprolol was evaluated on major adverse cardiovascular events (cardiac arrest, all-cause mortality, reinfarction, stroke, or hospitalization for heart failure) (ATE 2.9 percentage points, 95% CI 1.1-4.7). Atenolol initiation after myocardial infarction without heart failure was associated with a lower risk of major adverse cardiovascular events compared with bisoprolol.
Synapse has enriched 10 related papers. Consider them for comparative context: